Usage of cookies

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our Privacy policy.

Close
Skip to content

About Ascension

Everything we do is driven by a determination to make a difference where it really matters – people living their best life possible.


NEW APPROACHES TO OLD PROBLEMS:
Using patented technologies to treat people in unconventional ways

We differ from typical biopharma businesses in that we develop and sell, safe, high – quality and robustly tested alternatives to current drug products and therapies to retail customers and healthcare providers. Flexiseq, our product range for joint pain and stiffness are currently available across Europe in major pharmacies and supermarkets, and online where they have the potential to reach people suffering from osteoarthritis everywhere.

Headquartered in the UK, one of the top three world life sciences hubs, we operate globally. Our technologies dramatically increase the speed and precision with which we develop new treatments and products.

By accessing regional centres of excellence such as our clinical trials in Russia, our programme execution is accelerating our haematology treatments closer to approval stage. As we reduce risk and increase effectiveness in our products, the value we create for those suffering, and their families, who will ultimately benefit from our work is priceless.

Effective, Low cost, patient-centric solutions

Helping millions of people to a higher quality of life

The need for effective, affordable healthcare products for unmet or underserved diseases and markets is a pressing one for those who suffer from the conditions we target. Some of our drug-free treatments that have no side effects are already a commercial success, and our current research and development pipeline holds blockbuster potential.

Our team

Our management team

  • Biresh<br>Roy

    Biresh
    Roy

    Chief Executive Officer
  • Dr. Richard Garraway

    Dr. Richard Garraway

    Chief Operating Officer
  • Dr Gavin<br>Ling

    Dr Gavin
    Ling

    Chief Medical Officer
  • Shrikesh Shah

    Shrikesh Shah

    Finance Director
  • Dr. Sam<br> Yurdakul

    Dr. Sam
    Yurdakul

    Director of Development and Regulatory Affairs
  • Justin<br>Bowen

    Justin
    Bowen

    General Counsel

Biresh
Roy

Chief Executive Officer

Former Chief Financial Officer of Verona Pharma plc, a listed clinical stage bio-pharmaceuticals group.

Mr Roy is a strategic executive with a track record in executing and financing international M&A deals and delivering turnarounds, mainly in the bio-pharmaceuticals sector. He has acted as CFO for several biotech and medical device companies including Enigma Diagnostics, Xytis, Morphochem and Santhera.

Prior to this, he was a management consultant at A.T. Kearney and PwC leading international teams in large scale projects for big pharma and private equity backed pharmaceutical companies.

Mr Roy qualified as a Chartered Accountant with Price Waterhouse and holds a B.Sc. in economics from the London School of Economics.

Biresh<br>Roy

Dr. Richard Garraway

Chief Operating Officer

Dr. Garraway has over 30 years’ experience in developing, funding and commercialising novel technologies in the healthcare and bioscience sectors and is one of the founders of PBB.

He is an experienced director of technology companies both as a managing partner of private equity and VC funds, and also from 6 years at Imperial Innovations plc (now IP Group plc), heading their biotechnology incubator, creating, funding and mentoring companies with novel intellectual property. Prior to this he was an investment banker in the healthcare and FMCG M&A teams at JPMorgan and Robert Flemings investment banks.

Dr. Garraway holds a Ph.D. in biological sciences from the University of Portsmouth and an MBA from the London Business School.

Dr. Richard Garraway

Dr Gavin
Ling

Chief Medical Officer

Dr Ling is a Consultant Haematologist at Guy’s and St Thomas’ Hospital He trained at  University College London Hospital, a world class thrombosis and (thrombotic thrombocytopenic purpura (TTP) centre and the  Royal Free Hospital, a world renowned haemophilia training centre..

He qualified at St George’s, University of London with distinction for his medical degree in 2006 and is a Fellow of the Royal College of Pathologists since 2014.

Dr Ling is completing his PhD at University College London in  gene therapy for the treatment  of haemophilia, an area of cutting-edge translational science that has been revolutionising the treatment of haemophilia disorders and beyond.

Dr Gavin<br>Ling

Shrikesh Shah

Finance Director

Mr Shah has over 20 years of experience in Finance and has held leadership roles in private equity, listed and owner-managed businesses.

He was previously Interim CFO at Atlantic Healthcare Group, an emerging biotech pharma group. Prior to this, he was Senior Director, Finance for UK and Ireland at InterMune, a US NASDAQ listed international biotech pharma group, that was subsequently acquired by Roche Pharmaceuticals. And prior to that, he was Group Finance Director at Archimedes Pharma Group, a Private Equity backed international specialty pharma after ten years in public practice as an accountant, auditor and advisor.

Mr Shah is a qualified Chartered Accountant, with an MBA and holds a BA (Hons) in Economics.

Shrikesh Shah

Dr. Sam
Yurdakul

Director of Development and Regulatory Affairs

Dr Yurdakul has more than 30 years’ experience in leading product development from concept, through regulatory approval to commercialisation for major healthcare and consumer products companies including, Chiron Biopharma (Novartis), Boots Healthcare and Procter & Gamble. He has deep therapeutic area expertise in haemophilia and pain management, as well as experience in dermatology and infectious diseases.

Dr Yurdakul holds a Ph.D. in Physical Chemistry from Imperial College, London.

Dr. Sam<br> Yurdakul

Justin
Bowen

General Counsel

Former General Counsel for ten years at Imperial Innovations Group plc, a London listed spin-off from Imperial College London investing in biotech and industrial start-ups from leading scientific research universities in the UK.

Mr Bowen is an experienced director of legal affairs and company secretary, focussing particularly on corporate, financing and commercial matters mainly in the private equity and venture capital sectors. He has previously also acted as General Counsel at RAC plc and prior to that was a legal adviser at GEC plc. Mr Bowen qualified as a Barrister at Lincoln’s Inn, specialising in corporate and trust matters.

Justin<br>Bowen

Board of directors

Name Title Biography
Jon Aisbitt Chairman Former chairman of Man Group plc.; more than 20 years’ experience in international corporate finance and was previously partner and managing director in the Investment Banking Division of Goldman Sachs.
Biresh Roy CEO See management biography.
Dr Richard Garraway COO See management biography.
Michael Earl Non-executive and shareholder director Founder and shareholder of Pro Bono Bio. Former VP European Operations at Chiron and Commercial development at Celltech. Over 30 years in the healthcare industry at Smithkline Beecham, Abbott and Astra Zeneca.
Ali Baruni Non-executive director Over 37 years’ experience in the financial services industry; previously held senior roles in Bankers Trust Company and Citibank.
Oleg Kiselev Non-executive director Deputy chairman of the executive board of Rusnano Management Company LLC.
David Quint Non-executive director Founder and CEO of RP&C investment banking group.
Irina Rapoport Non-executive director CEO of Rusnano Capital; more than 20 years’ experience in management, investment and strategic planning; previously Managing Director of Renaissance Asset Management.
Dmitry Volokhov Non-executive director Investment director at Rusnano Corporation; more than 10 years’ experience in investment, valuation analysis and corporate finance.

Scientific advisory board

  • Edward Tuddenham

  • Dr Bill Henry

  • Dr Leysan Shaydullina

  • Dr Ulrich Thibaut

Edward Tuddenham

Edward Tuddenham is emeritus Professor of Haemophilia at University College London.

Prof. Tuddenham received his medical degree from the University of London in 1968. In his first post as a trainee pathologist at the Royal Victoria Infirmary in Liverpool, he developed a keen interest in haemophilia sparked by observing a patient with inhibitory antibody to factor VIII. For further training in haematology, he moved to Cardiff and started working on factor VIII under the guidance of Arthur Bloom, which he continued at the University of Connecticut, USA in the laboratory of Leon Hoyer. He was appointed as first director of the new Haemophilia Centre at Royal Free Hospital in London, where he was the immediate successor of Katharine Dormandy in 1978. From 1978 to 1982 his group completed the first large scale purification to homogeneity of human factor VIII. This enabled the sequencing of the protein, cloning of its gene and production of recombinant factor VIII in cultured cells, achieved in 1984 in collaboration with teams at Genentech Inc. In 1987 he left the Haemophilia Centre to set up the Haemostasis Research Group for the Medical Research Council, which he led for 20 years. During this time, his group made many advances in rare bleeding disorders such as deficiency of factor VII, factor XI, combined factor V and VIII and platelet function disorders. He returned to the Royal Free Hospital Katharine Dormandy Haemophilia Centre in 2006 and remained Director until his retirement in 2011. During that time his group initiated the first safe effective gene therapy for haemophilia B, work which was carried out in collaboration with Professor Amit Nathwani, (who became Tuddenham’s successor as Director of the Katharine Dormandy Haemophilia Centre) and teams at St Jude Children’s Research Hospital, Memphis, TN.

Prof. Tuddenham has published over 300 original scientific papers, review articles, book chapters and books

His current research interests are the establishment of gene therapies Haemophilia A, Haemophilia B and factor VII deficiency and the structure, function and interaction of factor VIII with other proteins. He is also interested in ways to make affordable therapy available worldwide in resource poor countries.

Dr Bill Henry

Dr Bill Henry studied as a BP scholar at the University of Edinburgh under the auspices of Sir John Cadogan. Bill was awarded a PhD in Organic Chemistry and went into industry as a development chemist specialising in process scale-up for the supply of pharmaceutical actives and intermediates. Bill joined the newly-formed Zeneca Bioproducts as a commissioning director, leading multi-disciplinary teams to commission airlift fermenters for the commercial supply of mycoprotein. Bill then accepted the position of European Operations Director for Sheering Plough to manage the supply and development of veterinary vaccines. Bill was invited to join a management buy-out team that acquired Grampian Pharmaceuticals and transformed the company into the biologics-focused Vericore. On successful exit by sale to Novartis, Bill joined Celltech as Technical Operations Director responsible for clinical supplies of antibodies and commercial supply of pharmaceutical products from plants in the USA and Europe.

Following Celltech’s acquisition, Bill joined PowderMed to commercialise their DNA vaccines, the success of which attracted the attention of Pfizer who acquired the DNA portfolio. Bill then joined Celtic Pharma, which transformed into Pro Bono Bio where he was Innovation Director and formed a focus on innovative technologies to deliver blood factors for haemophilia. After retirement from PBB, Bill was invited to join the Medical and Scientific development Advisory Board to help steer the company’s clinical programme to deliver novel methods for blood coagulation factors administration.

Dr Leysan Shaydullina

Leysan brings more than 10 years’ experience in venture capital industry and leads early stage investments in Life Science field at RUSNANO Venture department. Since October 2014, she is serving as Managing Director of management company RUSNANO LLC. From April 2009 to October 2014, she served as Investment Director of JSC RUSNANO Management Company and then of RUSNANO management company. She also served as an Associate at JSC RUSNANO from 2008 to 2009.

In 2008, Dr. Shaydullina served as a Senior Consultant with Regionatistica LLC, a Russian based consulting company. From 2004 to 2008, she was Head of the Investment Department and Manager of Innovative Projects at Innovative Technopark IDEA (Technopark), a Russian based business incubator, and worked with the companies on seed stage investments. Prior to Technopark, in 2004, Dr. Shaydullina served as a Senior Health Insurance Expert at ROSNO, now part of Allianz Insurance, a Russian insurance provider, and served as a Surgeon for the Children’s Republican Clinical Hospital of the Ministry of Health in Russia from 2002 to 2003.

Dr. Shaydullina received her MBA from the Academy of National Economy under the Government of the Russian Federation and her MD from Kazan State Medical University in Kazan, Russia.

Leysan is a member of the Board of Directors of several portfolio companies under RUSNANO’s supervision.

Dr Ulrich Thibaut

Dr Ulrich Thibaut studied Pharmacy and Pharmaceutical Chemistry at Tübingen University in Germany. On graduating and  and after qualifying  as Pharmacist, Ulrich obtaineda PhD in Pharmaceutical Chemistry and subsequently joined Byk Gulden GmbH (which later became ALTANA Pharma AG) as a research scientist, ). He served in various scientific and managerial roles in Research and Development and was appointed Executive Vice President Global R&D and member of the Executive Board of Management of ALTANA Pharma AG in 2004.

After the sale of ALTANA Pharma AG  to Nycomed in 2006 Ulrich  joined Drägerwerk AG in Lübeck, a global leader in the medical and safety device industry as Chief Technology Officer and Member of the Executive Board. His responsibilities included  the global R&D Organization of Dräger Medical AG, Dräger Safety AG and Drägerwerk AG’s basic research and development as well as the patent department.

In 2010 Ulrich joined Octapharma AG in Switzerland as Executive Board Member, with responsibility for the global R&D organization of the Octapharma Group. During his more than five years at Octapharma, several new developed products were successfully launched, (e.g. Nuwiq®, a recombinant FVIII produced in a human cell line and Panzyga®, a new IVIG product).

Ulrich has a broad managerial and scientific background from more than 27 years of R&D work in the health care industry and a proven track record of several large and successful product launches emerging from the R&D organizations he led.

Today Ulrich teaches  at the Swiss Federal Institute of Technology, and is a consultant   to  the pharmaceutical and medical device industry.